Ontario man says medication he's been taking for a decade just quadrupled in price
An Ontario man with Duchenne muscular dystrophy said he was shocked when he got his latest prescription filled for a medication he has been taking for the past ten years.
“I couldn’t believe it. I need to take this medication to help my muscles be able to work a bit better and it has almost quadrupled in price,” said 21-year-old Arun Crishanth of Aurora.
The medication is Deflazacort, a popular drug used to treat Duchenne muscular dystrophy, however it is not covered under government health plans.
The drug is a steroid taken daily to help keep muscles strong and symptoms of muscular dystrophy in check.
Crishanth said he used to get a four month supply of Deflazacort for $187, but when he got his last prescription filled it jumped to $666.
Crishanth was told by his pharmacy Pharmasave that the price increase was due to it being manufactured by a new drug company.
“This new company decided to turn around and quadruple the price. To me it seems ridiculous that they can increase the price that much," said Crishanth.
CTV News Toronto reached out to Pharmasave and a spokesperson said, “Pharmacy pricing in Canada is linked to the cost to purchase the medication from the manufacturer or distributor. The increased pricing experienced by pharmacies (and thus also to patients) is due to manufacturer and distributor changes.”
Deflazacort, a popular drug used to treat Duchenne muscular dystrophy, is photographed. CTV News Toronto also reached out to Muscular Dystrophy Canada and its CEO Stacey Lintern said in a statement, “Many individuals and their families have been advised by their doctors that Deflazacort is the most suitable option due to its minimal side effects, with some individuals having been on this treatment for 15 years or more. However, the significant increase in price will have detrimental effects on these individuals and their families.”
CTV News Toronto was unable to reach the new manufacturer of Deflazacourt, however Muscular Dystrophy Canada confirmed the price increase was due to a new manufacturer making the drug in Europe which also means increased shipping costs.
While there are cheaper alternatives, they have side effects and many patients with Duchenne muscular dystrophy feel that Deflazacourt is the preferred treatment.
"It’s a drug I’ve been taking for so many years, since I was 10 years old," said Crishanth, who said the drug will now cost him almost $2,000 a year.
"Obviously they should not be able to increase prices like that. It clearly isn't because of inflation, this is just to make some money and I think it's ridiculous that that can happen," said Crishanth.
Muscular Dystrophy Canada said it's important for patients to have equal access to appropriate treatments at a fair cost and that they will continue to try and influence change with regards to the price hike.
If you or your child is experiencing challenges accessing Deflazacort, you can contact Muscular Dystrophy Canada at research@muscle.ca or call 1-800-567-2873 ext. 1114.
CTVNews.ca Top Stories
Winnipeg man admits to killing four women, argues he's not criminally responsible
Defence lawyers of Jeremy Skibicki have admitted in court the accused killed four Indigenous women, but argues he is not criminally responsible for the deaths by way of mental disorder – this latest development has triggered a judge-alone trial rather than a jury trial.
NDP calls out Conservatives for effort to quash pharmacare legislation
The federal New Democrats are calling out Conservative Leader Pierre Poilievre and his party for trying to block the bill that could pave the way for millions of Canadians to access birth control and diabetes coverage.
Mediterranean staple may lower your risk of death from dementia, study finds
A daily spoonful of olive oil could lower your risk of dying from dementia, according to a new study by Harvard scientists.
DEVELOPING Hamas accepts Gaza ceasefire proposal from Egypt and Qatar
Hamas said it has accepted a ceasefire deal proposed by Egypt and Qatar which seeks to halt the seven-month war with Israel in Gaza.
An El Nino-less summer is coming. Here's what that could mean for Canada
As Canadians brace themselves for summer temperatures, forecasters say a weakening El Nino cycle doesn’t mean relief from the heat.
For the first time, researchers have identified a genetic form of late-in-life Alzheimer's disease
For the first time, researchers have identified a genetic form of late-in-life Alzheimer’s disease — in people who inherit two copies of a worrisome gene.
Manitoba Court of Appeal dismisses Peter Nygard's appeal of extradition order
The Manitoba Court of Appeal has dismissed Peter Nygard's application for a judicial review of an order to extradite the former fashion mogul to the United States, where he faces sex trafficking and racketeering charges.
Man banned from owning animals after fatal Calgary dog attack
The owner of three Calgary dogs that got loose and mauled a woman to death in 2022 has been ordered to pay a $15,000 fine within one year and banned from owning any animal for 15 years.
B.C. court date set for 3 accused of murdering Sikh activist Hardeep Singh Nijjar
Three suspects accused of murdering British Columbia Sikh activist Hardeep Singh Nijjar last year are scheduled to appear in court in Surrey on Tuesday.